Mallinckrodt Competitors

Spring Bank Pharmaceuticals (NASDAQ:SBPH) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Earnings & Valuation

This table compares Spring Bank Pharmaceuticals and Mallinckrodt's gross revenue, earnings per share (EPS) and valuation.

Spring Bank Pharmaceuticals has higher earnings, but lower revenue than Mallinckrodt. Spring Bank Pharmaceuticals is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spring Bank Pharmaceuticals and Mallinckrodt's net margins, return on equity and return on assets.

Risk and Volatility

Spring Bank Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Spring Bank Pharmaceuticals and Mallinckrodt, as provided by MarketBeat.

Spring Bank Pharmaceuticals currently has a consensus target price of $1.7333, suggesting a potential downside of 68.94%. Mallinckrodt has a consensus target price of $2.70, suggesting a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Spring Bank Pharmaceuticals.

Institutional and Insider Ownership

17.2% of Spring Bank Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 12.7% of Spring Bank Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mallinckrodt beats Spring Bank Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Verona Pharma (NASDAQ:VRNA) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Verona Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500.

Earnings and Valuation

This table compares Verona Pharma and Mallinckrodt's revenue, earnings per share and valuation.

Verona Pharma has higher earnings, but lower revenue than Mallinckrodt. Verona Pharma is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Verona Pharma and Mallinckrodt's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Verona Pharma and Mallinckrodt, as reported by MarketBeat.

Verona Pharma currently has a consensus price target of $22.75, indicating a potential upside of 213.36%. Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Verona Pharma.

Institutional & Insider Ownership

54.5% of Verona Pharma shares are held by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are held by institutional investors. 3.1% of Mallinckrodt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mallinckrodt beats Verona Pharma on 9 of the 13 factors compared between the two stocks.

Mallinckrodt (NYSE:MNK) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mallinckrodt and ObsEva, as reported by MarketBeat.

Mallinckrodt presently has a consensus price target of $2.70, indicating a potential upside of 831.03%. ObsEva has a consensus price target of $14.3333, indicating a potential upside of 589.10%. Given Mallinckrodt's higher possible upside, analysts plainly believe Mallinckrodt is more favorable than ObsEva.

Risk and Volatility

Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Earnings & Valuation

This table compares Mallinckrodt and ObsEva's top-line revenue, earnings per share and valuation.

ObsEva has lower revenue, but higher earnings than Mallinckrodt. ObsEva is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mallinckrodt and ObsEva's net margins, return on equity and return on assets.

Institutional & Insider Ownership

61.7% of Mallinckrodt shares are owned by institutional investors. Comparatively, 48.5% of ObsEva shares are owned by institutional investors. 3.1% of Mallinckrodt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mallinckrodt beats ObsEva on 9 of the 13 factors compared between the two stocks.

Kazia Therapeutics (NASDAQ:KZIA) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Valuation & Earnings

This table compares Kazia Therapeutics and Mallinckrodt's top-line revenue, earnings per share (EPS) and valuation.

Kazia Therapeutics has higher earnings, but lower revenue than Mallinckrodt. Kazia Therapeutics is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kazia Therapeutics has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Kazia Therapeutics and Mallinckrodt, as reported by MarketBeat.

Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts plainly believe Mallinckrodt is more favorable than Kazia Therapeutics.

Profitability

This table compares Kazia Therapeutics and Mallinckrodt's net margins, return on equity and return on assets.

Insider and Institutional Ownership

11.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 3.1% of Mallinckrodt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Mallinckrodt beats Kazia Therapeutics on 9 of the 12 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

51.2% of Aravive shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Aravive and Mallinckrodt's top-line revenue, earnings per share (EPS) and valuation.

Aravive has higher earnings, but lower revenue than Mallinckrodt. Aravive is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aravive and Mallinckrodt, as reported by MarketBeat.com.

Aravive currently has a consensus price target of $26.20, suggesting a potential upside of 365.36%. Mallinckrodt has a consensus price target of $2.70, suggesting a potential upside of 831.03%. Given Mallinckrodt's higher probable upside, analysts plainly believe Mallinckrodt is more favorable than Aravive.

Risk and Volatility

Aravive has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, indicating that its stock price is 206% more volatile than the S&P 500.

Profitability

This table compares Aravive and Mallinckrodt's net margins, return on equity and return on assets.

Rockwell Medical (NASDAQ:RMTI) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Rockwell Medical and Mallinckrodt's net margins, return on equity and return on assets.

Insider & Institutional Ownership

21.1% of Rockwell Medical shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 4.7% of Rockwell Medical shares are owned by insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Rockwell Medical and Mallinckrodt's gross revenue, earnings per share (EPS) and valuation.

Rockwell Medical has higher earnings, but lower revenue than Mallinckrodt. Rockwell Medical is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Rockwell Medical and Mallinckrodt, as provided by MarketBeat.com.

Rockwell Medical presently has a consensus price target of $9.00, indicating a potential upside of 749.06%. Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Rockwell Medical.

Risk & Volatility

Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500.

Summary

Mallinckrodt beats Rockwell Medical on 8 of the 14 factors compared between the two stocks.